Patent application number | Description | Published |
20130324496 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: | 12-05-2013 |
20140212487 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising ledipasvir, wherein ledipasvir is dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer, and further wherein ledipasvir is substantially amorphous. Also disclosed are pharmaceutical compositions comprising solid dispersion and methods of using the solid dispersion. | 07-31-2014 |
20140212491 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 07-31-2014 |
20150064252 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising a compound having the formula: | 03-05-2015 |
20150064253 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions comprising Compound I, having the formula: | 03-05-2015 |
20150344488 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5 -(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro [2 .4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: | 12-03-2015 |
20160120892 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 05-05-2016 |